Annexon, Inc. (ANNX) Stock AnalysisANNXStock AnalysisAnnexon, Inc.

Annexon, Inc. is a clinical-stage biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye. It identifies and characterizes the role of the classical complement pathway in three therapeutic areas: autoimmune, neurodegeneration and ophthalmology, using its proprietary platform. Its lead candidate, ANX005, an investigational, full-length monoclonal antibody (mAb), is formulated for intravenous administration as the potential first targeted treatment for patients with Guillain-Barre Syndrome (GBS). It is advancing ANX1502, a novel small-molecule inhibitor of classical complement designed for oral administration in a range of chronic autoimmune diseases. It is also advancing ANX007, designed to block C1q locally in the eye, to provide complete protection against excess classical complement activity and the loss of photoreceptor neurons. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Annexon Inc (ANNX) is a good buy right now due to its current price of $4.97, which is significantly lower than the analyst price target of $25 from Needham, indicating a potential upside of over 400%. Additionally, the stock has shown a remarkable 140.10% increase over the past year, suggesting strong long-term growth potential. However, the main risk is the ongoing net losses, which reached $55.3 million in Q2 2026, reflecting a challenging financial environment.